Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Immatics N.V. Ordinary Shares (IMTX)

https://www.immatics.com

Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/02/2020

Market Cap

1,180,987,380

Shares Outstanding

80,400,000

Weighted SO

84,656,114

Total Employees

N/A

Upcoming Earnings

08/15/2024

Similar Tickers

CRNX --.--%

ALXO --.--%

BCAB --.--%

AVTE --.--%

KROS --.--%

SNDX --.--%

MLYS --.--%

REPL --.--%

JANX --.--%

Beta

0.7470

Last Div

0.0000

Range

7.15-13.77

Chg

-0.0400

Avg Vol

432145

Mkt Cap

1180987380

Exch

NASDAQ

Country

DE

Phone

49 7071 5397 0

DCF Diff

18.6810

DCF

-7.1810

Div Yield

0.0000

P/S

15.0847

EV Multiple

-11.4991

P/FV

2.7656

Div Yield %

0.0000

P/E

-14.5401

PEG

-0.5199

Payout

0.0000

Current Ratio

3.7388

Quick Ratio

3.7388

Cash Ratio

1.0575

DSO

18.5523

DIO

0.0000

Op Cycle

18.5523

DPO

71.5109

CCC

-52.9586

Gross Margin

-0.3489

Op Margin

-1.4234

Pretax Margin

-1.0164

Net Margin

-1.0376

Eff Tax Rate

-0.0268

ROA

-0.1177

ROE

-0.2340

ROCE

-0.2120

NI/EBT

1.0209

EBT/EBIT

0.7141

EBIT/Rev

-1.4234

Debt Ratio

0.0574

D/E

0.0928

LT Debt/Cap

0.0354

Total Debt/Cap

0.0849

Int Coverage

-108.9406

CF/Debt

-0.4821

Equity Multi

1.6164

Rec Turnover

19.6741

Pay Turnover

5.1041

Inv Turnover

999999.9999

FA Turnover

1.0955

Asset Turnover

0.1134

OCF/Share

-0.1685

FCF/Share

-0.4376

Cash/Share

5.1558

OCF/Sales

-0.2441

FCF/OCF

2.5972

CF Coverage

-0.4821

ST Coverage

-0.7970

CapEx Coverage

-0.6261

Div&CapEx Cov

-0.6261

P/BV

2.7656

P/B

2.7656

P/S

15.0847

P/E

-14.5401

P/FCF

-23.7946

P/OCF

-61.8106

P/CF

-61.8106

PEG

-0.5199

P/S

15.0847

EV Multiple

-11.4991

P/FV

2.7656

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Nov 08, 22:00 Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME GlobeNewswire Inc. Oct 11, 00:50 Immatics Announces Pricing of $150 Million Public Offering GlobeNewswire Inc. Jan 17, 20:30 Immatics Announces Pricing of $175 Million Public Offering GlobeNewswire Inc. Jan 17, 20:30 Immatics Announces Pricing of $175 Million Public Offering GlobeNewswire Inc. Jan 17, 20:30 Immatics Announces Pricing of $175 Million Public Offering GlobeNewswire Inc. Jan 17, 20:30 Immatics Announces Pricing of $175 Million Public Offering

Revenue Product Segmentation